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STATE OF MAINE

SUPERIOR COURT

KENNEBEC, SS.

CIVIL ACTION
Docket No.

STATE OF MAINE,

Plaintiff
v.
CONSENT JUDGMENT
PURDUE PHARMA L.P., et al.,

Defendant

Plaintiff, State of Maine, acting through Attorney General G. Steven Rowe, has
brought this action pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.A. § 205A et seq., having filed a complaint against Purdue Pharma Inc., Purdue Pharma L.P. and
The Purdue Frederick Company Inc. (d/b/a The Purdue Frederick Company) (hereinafter
“Purdue”). The parties having consented to the entry of this Consent Judgment for the
purposes of settlement only, without constituting evidence against or any admission by
any party, and without trial of any issue of fact or law, IT IS HEREBY ORDERED,
ADJUDGED AND DECREED AS FOLLOWS:
/
This Consent Judgment (hereinafter referred to as “Judgment”) is entered into
between the Attorneys General or other entities1of the States and Commonwealths of

1For the putposes of this agreement, when the entire group is referred to as “Signatory
Attorneys General,” such designation, as it pertains to CONNECTICUT, shall refer to the
Commissioner of the Department o f Consumer Protection, who enters this Consent
1
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Arizona, Arkansas, California, Connecticut, District of Columbia, Idaho, Illinois,
Kentucky, Louisiana, Maine, Maryland, Massachusetts, Montana, Nebraska, Nevada,
New Mexico, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee,
Texas, Vermont, Virginia, Washington, and Wisconsin (hereinafter referred to as
“Signatory Attorneys General”), acting on behalf of their respective states, and pursuant
to their respective consumer protection statutes; and Purdue.
I.
1.

DEFINITIONS

The following definitions shall be used in construing this Consent

Judgment (hereinafter "Judgment”):
A.

“Covered Persons” shall mean all officers, employees and all contract or

third-party sales representatives, including Medical Liaisons, o f Purdue or retained by
Purdue having direct responsibility for marketing and promoting OxyContin to Health
Care Professionals.
B.

“Effective Date” shall mean the date on which Purdue receives a copy of

this Judgment, duly executed by Purdue and by the Signatory Attorney General and filed
with the Court.
C.

“FDA Guidances for Industry” shall mean documents published by the

United States Department o f Health and Human Services, Food and Drug Administration
(“FDA”) that represent the FDA’s current recommendations on a topic.
pursuant to the Connecticut Unfair Trade Practices Act, Conn. Gen. Stat, Sec. 42-1 lOj,
acting by and through his counsel, Richard Blumenthal, Attorney General for the State of
Connecticut. For MONTANA, such designation shall refer to the Consumer Protection
Office of the Department o f Justice who enters into this settlement pursuant to the
Montana Unfair Trade and Consumer Protection Act o f 1973 MCA 30-14-101 et al.,
acting by and through his counsel, Mike McGrath, Attorney General for the State of
Montana.
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D.

“Health Care Professional” or “Health Care Professionals” shall mean any

person or persons duly licensed by relevant federal and/or state law to prescribe Schedule
II pharmaceutical products, as well as duly licensed pharmacists, nurses and other
licensed health professionals.
E.

“Off-Label Promotion” shall mean the marketing and promotion of an

Off-Label Use. Off-Label Promotion shall not mean discussion of the abuse and
diversion of OxyContin that is not inconsistent with the Package Insert.
F.

"Off-Label Use” shall mean any use inconsistent with the “Indications and

Usage” section of the Package Insert.
G.

“OxyContin” shall mean any controlled-release drug distributed by Purdue

which contains oxycodone as an active pharmaceutical ingredient.
H.

“Package Insert” shall mean the FDA approved label (as described in 21

C.F.R. §§ 201.56 and 57) for OxyContin, including all modifications to the label
theretofore approved by the FDA.
I.

"Parties” shall mean Purdue and the Signatory Attorneys General.

J.

“Purdue" shall mean Purdue Pharma Inc,, Purdue Pharma L.P., The

Purdue Frederick Company, Inc. (d/b/a The Purdue Frederick Company), and all of their
United States affiliates, subsidiaries, predecessors, successors, parents and assigns, who
manufacture, sell, distribute and/or promote OxyContin.
K.

“Remuneration” shall mean any gift, fee, or payment, exceeding twenty-

five dollars ($25.00) in value, provided by Purdue directly or indirectly in connection
with marketing or promotion of OxyContin.
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L.

“Signatory Attorney General” shall mean the Attorney General, or his or

her designee, who has agreed to this Judgment.
M.

“Subject Matter of this Judgment” shall mean the investigation under the

State Consumer Protection Laws2 of Purdue’s promotional and marketing practices
regarding OxyContin.

2 ARIZONA Consumer Fraud Act, Ariz. Rev. Stat. §44-1521, et seq.; ARKANSAS Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101 e t s e q CALIFORNIA
Business and Professions Code § 17200 etseq. 17500 etseq.; CONNECTICUT Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. §42-110 etseq.; DISTRICT
OF COLUMBIA - District o f Columbia Consumer Protection Procedures Act, D.C, Code
§ 28-3901 etseq.; IDAHO - Consumer Protection Act, Idaho Code § 48-601 etseq.;
ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815 ILCS § 505/1 et
seq. (2002); KENTUCKY - Consumer Protection Statute, KRS 367.170; LOUISIANA Unfair Trade Practices and Consumer Protection Law, LSA-R.S. 51:1401 et seq.;
MAINE - Unfair Trade Practices Act, 5 M.R.S.A. section 205-A etseq.; MARYLAND Consumer Protection Act, Maryland Commercial Law Code Annotated § 13-101 etseq.;
MASSACHUSETTS - Consumer Protection Act, M.G.L. c. 93A et seq.; MONTANA Mont. Code Ann. § 30-14-101 etseq.; NEBRASKA - Consumer Protection Act:
Neb.Rev.Stat. 59-1601, et seq. (Reissue 2004 & RS Supp. 2006), Uniform Deceptive
Trade Practices Act: Neb.Rev.Stat. 87-301 etseq. (Reissue 1999 & RS Supp. 2006);
NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NEW M EXICO-Unfair Practices Act" NMSA 1978, S 57-12-1 etseq. (1967); NORTH
CAROLINA - Unfair and Deceptive Trade Practices Act, N.C.G.S. § 75-1.1 et seq.;
OHIO - Consumer Sales Practices Act, R.C. § 1345.01 et seq.; OREGON - Unlawful
Trade Practices Act, ORS 646.605 to 646.656; PENNSYLVANIA - Unfair Trade
Practices and Consumer Protection Law, 73 P.S. § 201-1 etseq.; SOUTH CAROLINA Unfair Trade Practices Act, Sections 39-5-10 et seq.; TENNESSEE - Consumer
Protection Act, Tenn. Code Ann. § 47-18-101 etseq., (1977); TEXAS - Deceptive Trade
Practices and Consumer Protection Act, Tex. Bus. And Com. Code § 17.41 etseq.,
(Vernon 2002); VERMONT - Consumer Fraud Act, 9 V.S.A. § 2451 et seq.; VIRGINIA
- Virginia Consumer Protection Act, Va. Code Ann, § 59.1 -196 et seq.; WASHINGTON
- Washington Consumer Protection Act - R.C.W. 1986 et seq.; WISCONSIN - Wis. Stat.
§ 100.18 (Fraudulent Representations).
4
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2.

COMPLIANCE PROVISIONS

In the promotion and marketing of OxyContin, Purdue shall not make any

written or oral claim that is false, misleading or deceptive.
3,

In the promotion and marketing of OxyContin, Purdue shall not market or

promote OxyContin in a manner that is, directly or indirectly, inconsistent with the
“Indication and Usage” section o f the Package Insert for OxyContin. Further, Purdue
shall, consistent with the Package Insert, or as otherwise permitted by the FDA, not
promote or market OxyContin in a manner that: (a) avoids or minimizes the fact that
OxyContin is indicated for moderate to severe pain when a continuous around-the-clock
analgesic is needed for an extended period of time; or (b) avoids, minimizes, or is
inconsistent with individualizing treatment using a plan of pain management, such as
outlined by the World Health Organization, the Agency for Healthcare Research and
Quality (formerly known as the Agency for Healthcare Policy and Research), the
Federation of State Medical Boards Model Guidelines or the American Pain Society, as
referenced in the Package Insert.
4.

In the promotion and marketing of OxyContin, Purdue shall provide “fair

balance” statements, as defined in 21 C.F.R, § 202.1 as may be amended or •
supplemented, or as appearing in FDA Guidances for Industry from time to time,
regarding contraindications and adverse events, including but not limited to statements
regarding OxyContin’s potential for abuse, addiction, or physical dependence as set forth
in the Package Insert.
5.

In the promotion and marketing of OxyContin, Purdue shall not make

misrepresentations with respect to OxyContin’s potential for abuse, addiction, or physical
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dependence as set forth in the Package Insert. Further to this general prohibition on
misrepresentations, Purdue, in the promotion and marketing of OxyContin, shall not
represent, except as may be set forth in the Package Insert, that: a) OxyContin is
“nonaddictive” or “virtually nonaddictive”; b) addiction to OxyContin occurs in “less
than 1%” of patients being treated with OxyContin; or c) OxyContin *s potential for
abuse, addiction or physical dependence differs from any other Schedule II opioid
analgesic.
6.

In the promotion and marketing of OxyContin, Purdue shall not make any

written or oral promotional claim of safety or effectiveness for Off-Label Uses of
OxyContin in a manner that violates the Food, Drug and Cosmetic Act, 21 U.S.C. § 301

efseq. (“FDCA”), and accompanying regulations as may be amended or supplemented,
or as appearing in FDA Guidances for Industry from time to time.
7.

Except upon a request for such information without solicitation by Purdue

to make the request, Purdue shall not provide to Health Care Professionals written
materials describing the Off-Label Use of OxyContin that have not appeared in a
scientific or medical journal or reference publication or any portion thereof. Purdue shall
maintain records for three (3) years of the identity of all Health Care Professionals to
whom such materials relating to the Off-Label Use of OxyContin have been provided.
"Scientific or medical journal” is a publication whose articles are published in accordance
with regular peer-reviewed procedures; that uses experts to review or provide comment
on proposed articles; and that is not in the form of a special supplement that has been
funded in whole or in part by one or more manufacturers. “Reference publication” is a
publication that has no common ownership or other corporate affiliation with a
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pharmaceutical or medical device manufacturer; that has not been written, edited,
excerpted, or published specifically for, or at the request of, such a manufacturer; and that
has not been edited or significantly influenced by such a manufacturer.
8.

A.

When Purdue provides an individual or entity with any educational

grant, research grant, or other similar Remuneration relating to OxyContin, Purdue shall
obtain the recipient’s agreement: (i) to clearly and conspicuously disclose the existence of
said funding or Remuneration to the readers of any resulting letter, study, research or
other materials which was supported by said funding or Remuneration, and (ii) to refund
said funding or Remuneration if such disclosure is not made.
B.

Purdue shall require that a recipient of any Remuneration from Purdue for

the promotion of OxyContin agree: (i) to clearly and conspicuously disclose the
existence, nature and purpose of the Remuneration to the participants in any educational
event at which the recipient discusses an Off-Label Use of OxyContin, and (ii) to refund
said Remuneration if such disclosure is not made.
C.

Purdue shall itself clearly and conspicuously disclose the existence of any

grant or other form o f Remuneration that it has provided for the publication of a letter,
study, research or other material relating to OxyContin when Purdue disseminates or
refers to said letter, study, research or other material in communications with Health Care
Professionals.
9.

Purdue shall comply with all applicable Accreditation Council for

Continuing Medical Education (“ACCME”) Guidelines.
10.

Purdue shall comply with paragraphs 2 ,3 ,4 , 5,7 and 8 of the

Pharmaceutical Research and Manufacturers of America Code (effective on July 1, 2002)
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with respect to payments, gifts and other compensation to Health Care Professionals
regarding OxyContin.
11.

In the promotion and marketing of OxyContin, Purdue shall not

misrepresent the existence, non-existence, or findings of any medical or scientific
evidence, including anecdotal evidence, relating to Off-Label Uses of OxyContin.
Purdue shall not provide any information that is misleading or lacking in fair balance, as
defined in 21.C.F.R. 202.1, as may be amended or supplemented, or as appearing in
FDA Guidances for Industry from time to time, in any discussion of the Off-Label Uses
of OxyContin.
12.

Purdue shall not sponsor or fund any educational events where Purdue has

knowledge at the time the decision for sponsorship or funding is made that a speaker will
recommend the Off-Label Use of OxyContin. Further, Purdue shall not promote or fund
Health Care Professionals’ attendance at educational events where Purdue has
knowledge, at the time of said promotion, that Off-Label Use of OxyContin will be
recommended or encouraged.
13. Purdue shall, no later than thirty (30) business days after the Effective Date of
this Judgment, establish, implement and follow an OxyContin abuse and diversion
detection program consisting of internal procedures designed to identify potential abuse
or diversion of OxyContin in certain settings (the “OxyContin Abuse and Diversion
Detection Program”). The OxyContin Abuse and Diversion Detection Program will
apply to Purdue employees and contract or third-party sales representatives, including
Medical Liaisons, who contact practicing Health Care Professionals in person or by
telephone for the purpose of promoting OxyContin. That Program directs those persons
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to report to the Office of the General Counsel situations, including, but not limited to the
following examples, to the extent that such information or activities are observed or
learned of by them: a) an apparent pattern of an excessive number of patients for the
practice type, such as long lines of patients waiting to be seen, waiting rooms filled to
standing-room-only capacity, or patient-prescriber interactions that are exceedingly brief
or non-existent; b) an atypical pattern of prescribing techniques or locations, such as
repeated prescribing from an automobile, or repeated prescribing at atypical times, such
as after usual office hours when the Health Care Professional is not on call; c)
information from a highly credible source or several sources (e.g., pharmacists, law
enforcement, other health care workers) that a Health Care Professional or their patients
are abusing or diverting medications; d) sudden, unexplained changes in prescribing or
dispensing patterns that are not accounted for by changes in patient numbers or practice
type; e) a Health Care Professional who has a disproportionate number of patients who
pay for office visits and dispensed medications with cash; f) multiple allegations that
individuals from a particular practice have overdosed; or g) unauthorized individuals
signing prescriptions or dispensing controlled substances. Upon identification of
potential abuse or diversion involving a Health Care Professional with whom Purdue
employees or its contract or third-party sales representatives, including Medical Liaisons,
interact, Purdue will conduct an internal inquiry which will include but not be limited to a
review of the Health Care Professional’s prescribing history, to the extent such history is
available and relevant, and shall take such further steps as may be appropriate based on
the facts and circumstances, which may include ceasing to promote Purdue products to
the particular Health Care Professional, providing further education to the Health Care
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Professional about appropriate use o f opioids, or providing notice of such potential abuse
or diversion to appropriate medical, regulatory or law enforcement authorities. Purdue's
obligations under this Section shall expire ten (10) years following the Effective Date of
this Judgment or three months from the date on which the last of Purdue’s patents
covering OxyContin expires, whichever is earlier, but in no event shall be earlier than
seven (7) years following the Effective Date of this Judgment.
14.

Purdue shall implement and maintain a training and education program

with respect to the OxyContin Abuse and Diversion Detection Program, and shall require
all Purdue employees and contract or third-party sales representatives, including Medical
Liaisons, who contact practicing Health Care Professionals in person or by telephone for
the purpose of promoting OxyContin to complete the training and education program no
later than thirty (30) business days after the Effective Date of this Judgment. Further,
Purdue shall require those Purdue employees and contract or third-party sales
representatives, including Medical Liaisons, who contact practicing Health Care
Professionals in person or by telephone for the purpose of promoting OxyContin to
complete the training and education program before being allowed to market or promote
OxyContin, Purdue’s obligations under this Section shall expire ten (10) years following
the Effective Date of this Judgment or three months from the date on which the last of
Purdue’s patents covering OxyContin expires, whichever is earlier, but in no event shall
be earlier than seven (7) years following the Effective Date of this Judgment.
15.

Within 90 days o f the Effective Date of this Judgment, Purdue shall

provide to each Health Care Professional whom Covered Persons contact, written, nonbranded educational information related to detecting and preventing abuse and diversion
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of opioid analgesics. To the extent that Purdue concludes that a specific Health Care
Professional needs repeated exposure to such non-branded educational materials, Purdue
will provide those materials, Purdue’s obligations under this Section will remain in effect
for ten (10) years following the Effective Date of this Judgment.
16.

Purdue shall continue to review news media stories addressing the abuse

or diversion of OxyContin and undertake appropriate measures as reasonable under the
circumstances to address abuse and diversion so identified, including but not limited to,
(i) correcting misinformation, (ii) offering non-branded educational materials to local
substance abuse prevention and treatment initiatives, or (iii) directing Health Care
Professionals to Purdue’s Medical Services group for fair and balanced information on
appropriate use of opioid analgesics, prevention and detection of abuse and diversion.
Purdue’s obligations under this Section shall expire ten (10) years following the Effective
Date of this Judgment or three months from the date on which the last of Purdue’s patents
covering OxyContin expires, whichever is earlier, but in no event shall be earlier than
seven (7) years following the Effective Date of this Judgment.
17.

No sales incentive (bonus) program for sales of OxyContin shall allow

incentive credit to be earned for a Health Care Professional who has been identified
through the OxyContin Abuse and Diversion Detection Program as one upon whom sales
representatives shall not call. In addition, Purdue shall not employ a compensation
structure for persons involved in marketing or promoting OxyContin that is based
exclusively on the volume of OxyContin sales.
18.

For a period of ten (10) years following the Effective Date of this

Judgment, Purdue’s performance evaluation of persons involved in marketing or

11

promoting OxyContin shall meaningfully take into account that sales persons inform
Health Care Professionals to whom the sales persons promote OxyContin about its
potential for abuse and diversion, and how to minimize those risks; failure to do so shall
be considered as a basis for disciplinary action, including, but not limited to censure,
probation and termination.
19.

In its promotion and marketing of OxyContin, Purdue shall not

misrepresent, in any written or oral claim relating to OxyContin, that its sales, medical or
research personnel have experience or credentials or are engaging in research activities if
they do not in fact possess such credentials or experience, or are not engaging in such
activities.
20.

All material used in promoting OxyContin, regardless of format (audio,

internet, video, print) and whether directed primarily to patients or to Health Care
Professionals, shall, not inconsistent with the Package Insert, contain only information
that is truthful, balanced, accurately communicated, and not minimize the risk of abuse,
addiction or physical dependence associated with the use of OxyContin.
2 1.

Purdue shall not provide samples of OxyContin to Health Care

Professionals.
22.

The obligations of Purdue under this Judgment shall be prospective only.

No Signatory Attorney General shall institute any proceeding or take any action against
Purdue under its State Consumer Protection Laws or any similar state authority, or under
this Judgment, based on Purdue’s prior promotional or marketing practices for
OxyContin.
23.

Nothing in this Judgment shall require Purdue to:
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take an action that is prohibited by the FDCA, the Controlled Substances

Act or any regulation promulgated thereunder, or by FDA or the Drug Enforcement
Administration;
(b)

fail to take an action that is required by the FDCA, the Controlled

Substances Act or any regulation promulgated thereunder, or by FDA or the Drug
Enforcement Administration;
(c)

refrain from dissemination of safety information concerning OxyContin;

(d)

refrain from making any written or oral promotional claim which is the

or

same or substantially the same as the language permitted by FDA under the OxyContin
Package Insert and which accurately portrays the data or other information referenced in
the OxyContin Package Insert.
24.

Purdue shall:

(a)

to the extent necessary for compliance with this Judgment, no later than

ninety (90) days after the Effective Date of this Judgment, institute compliance
procedures which are designed to begin training currently employed Covered Persons on
the contents of this Judgment, and about how to comply with this Judgment;
(b)

submit to the Attorney General (per the Notice below), no later than one

hundred and twenty (120) days after the Effective Date of this Judgment, a written
description of such training;
(c)

submit to the Attorney General (per the Notice below), one (1) year after

the Effective Date of this Judgment, a written affirmation setting forth Purdue’s
compliance with this paragraph;
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(d)

for a period of three (3) years from the Effective Date of this Judgment,

Purdue shall advise in writing all Covered Persons of the requirements of Paragraphs 2
through 23 of this Judgment;
(e)

beginning one (1) year after the Effective Date of this Judgment, for a

period of three (3) years, produce and provide on an annual basis to the Attorney General
on the anniversary of the Effective Date of this Consent Judgment a report containing
basic statistics on Purdue’s Abuse and Diversion Detection Program including, but not
limited to, statistics on the number of reports, the number of investigations, and a
summary of the results, including the number o f “Do Not Call” determinations, but shall
not include the names of any specific Health Care Professionals; and
(i)

upon written request, the Attorney General may obtain state-specific

information as described in subsection (e). In addition, Purdue agrees to accept service
of a civil investigative demand or similar process by the Attorney General requesting the
names of any specific Health Care Professionals described in subsection (e). The
Attorney General in receipt of such information shall not disclose it except as provided
by law,

in.
25.

PAYMENT TO TH E STATES

No later than thirty (30) days after the Effective Date of this Judgment,

Purdue shall pay nineteen million and five hundred thousand U.S. dollars
($19,500,000.00, to be paid by Purdue to the States by electronic fund transfer made
payable to the Oregon Department of Justice (as instructed by that Office) which shall
divide and distribute these funds as designated by and in the sole discretion of the
Signatory Attorneys General as part of the consideration for the termination of their
respective investigations under the State Consumer Protection Laws regarding the
14
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Subject Matter of this Judgment. Said payment shall be used by the States as and for
attorneys’ fees and other costs o f investigation and litigation, or to be placed in, or
applied to, the consumer protection enforcement fund, including future consumer
protection enforcement, consumer education, litigation or local consumer aid fund or
revolving fund, used to defray the costs of the inquiry leading hereto, and may be used to
fund or assist in funding programs directed at combating prescription drug abuse,
addiction and/or diversion, including, but not limited to, education, outreach, prevention
or monitoring programs, or for other uses permitted by state law, at the sole discretion of
each Signatory Attorney General.

IV.

GENERAL PROVISIONS

26.

This Judgment shall be governed by the laws of the State of Maine.

27.

This Judgment is entered into by the Parties as their own free and

voluntary act and with full knowledge and understanding of the nature of the proceedings
and the obligations and duties imposed by this Judgment.
28.

Nothing in this Judgment constitutes any agreement by the Parties

concerning the characterization of the amounts paid pursuant to this Judgment for
purposes of the Internal Revenue Code or any state tax laws, or the resolution of any
other matters.
29.

This Judgment does not constitute an approval by the Attorney General of

any o f Purdue’s business practices, including its promotional or marketing practices, and
Purdue shall make no representation or claim to the contrary.
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V.
30.

REPRESENTATIONS AND WARRANTIES

Purdue warrants and represents that it and its predecessors, successors and

assigns manufactured, sold and promoted OxyContin, Purdue further acknowledges that
it is a proper party to this Judgment, Purdue further warrants and represents that the
individual(s) signing this Judgment on behalf of Purdue is doing so in his (or her) official
capacity and is fully authorized by Purdue to enter into this Judgment and to legally bind
Purdue to all o f the terms and conditions of the Judgment..
31.

Each o f the Parties represents and warrants that it negotiated the terms of

this Judgment in good faith.
32.

Each of the Signatory Attorneys General warrants and represents that he

or she is signing this Judgment in his or her official capacity, and that he or she is fully
authorized by his or her state to enter into this Judgment, including but not limited to the
authority to grant the release contained in Paragraphs 34 and 35 of this Judgment, and to
legally bind the state to all of the terms and conditions of this Judgment.
33.

Purdue acknowledges and agrees that the Attorney General has relied on

all o f the representations and warranties set forth in this Judgment and that, if any
representation is proved false, unfair, deceptive, misleading, or inaccurate in any material
respect, the Attorney General has the right to seek any relief or remedy afforded by law
or equity in the state.
VI.
34.

RELEASE

Based on his or her inquiry into Purdue’s promotion of OxyContin, the

Attorney General has concluded that this Judgment is the appropriate resolution o f any
alleged violations of the State Consumer Protection Laws. The Attorney General
acknowledges by his or her execution hereof that this Judgment terminates their inquiry
16
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under the State Consumer Protection Laws into Purdue’s promotion of OxyContin prior
to the Effective Date of this Judgment.
35.

In consideration of the Compliance Provisions, payments, undertakings,

and acknowledgments provided for in this Judgment, and conditioned on Purdue’s
making full payment of the amount specified in Paragraph 25, and subject to the
limitations and exceptions set forth in Paragraph 36, the State releases and forever
discharges, to the fullest extent permitted by law, Purdue and its past and present officers,
directors, shareholders, employees, co-promoters, affiliates, parents, subsidiaries,
predecessors, assigns, and successors (collectively, the “Releasees”), of and from any and
all civil causes of action, claims, damages, costs, attorney’s fees, or penalties that the
Attorney General could have asserted against the Releasees under the State Consumer
Protection Law by reason of any conduct that has occurred at any time up to and
including the Effective Date of this Judgment relating to or based upon the Subject
Matter of this Judgment (“Released Claims”).
36.

The Released Claims set forth in Paragraph 35 specifically do not include

the following claims:
(a)

private rights of action by consumers, provided, however, that this

Judgment does not create or give rise to any such private right of action of any kind;
(b)

claims relating to Best Price, Average Wholesale Price or Wholesale

Acquisition Cost reporting practices or Medicaid fraud or Abuse;
(c)

claims of antitrust, environmental or tax liability;

(d)

claims for property damage;

(e)

claims to enforce the terms and conditions of this Judgment; and
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(f)

any state or federal criminal liability that any person or entity, including

Releasees, has or may have to the State.
VII.
37.

NO ADMISSION OF LIABILITY

This Judgment does not constitute an admission by Purdue for any

purpose, of any fact or of a violation of any state law, rule, or regulation, nor does this
Judgment constitute evidence of any liability, fault, or wrongdoing, by Purdue nor does
Purdue’s agreement in this Judgment not to engage in certain conduct constitute an
admission that Purdue has ever engaged in such conduct. Purdue enters into this
Judgment for the purpose of resolving the concerns o f the Attorney General regarding
Purdue’s promotional and marketing practices regarding OxyContin. Purdue does not
admit any violation of the State Consumer Protection Laws, and does not admit any
wrongdoing that could have been alleged by the Attorney General.
38.

This Judgment shall not be construed or used as a waiver or any limitation

of any defense otherwise available to Purdue. This Judgment is made without trial or
adjudication of any issue o f fact or law or finding of liability of any kind. Nothing in this
Judgment, including this paragraph, shall be construed to limit or to restrict Purdue’s
right to use this Judgment to assert and maintain the defenses of res judicata, collateral
estoppel, payment, compromise and settlement, accord and satisfaction, or any other legal
or equitable defenses in any pending or future legal or administrative action or
proceeding.
VIII.

39.

DISPUTES REGARDING COMPLIANCE

For the purposes of resolving disputes with respect to compliance with this

Judgment, should the Attorney General have legally sufficient cause (which shall include,
at a minimum, a reasonable basis to believe that Purdue has violated a provision of this
18
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Judgment) to object to any promotional or marketing practices relating to OxyContin
subsequent to the Effective Date of this Judgment, then the Attorney General shall notify
Purdue in writing of the specific objection, identify with particularity the provisions of
this Judgment and/or the State Consumer Protection Laws that the practice appears to
violate, and give Purdue thirty (30) business days to respond to the notification; provided,
however, that the Attorney General may take any action upon notice to Purdue where the
Attorney General concludes that, because of the specific practice, a threat to the health or
safety o f the public requires immediate action.
40.

Upon receipt of written notice and within the thirty (30) business-day

period, Purdue shall provide a good faith written response to the Attorney General’s
objection. The response shall include an affidavit containing either:
a.

A statement explaining why Purdue believes it is in compliance with the

Judgment; or
b.

A detailed explanation of how the alleged violation[s] occurred; and
i.

A statement that the alleged breach has been cured and how it has

been cured; or
ii.

A statement that the alleged breach cannot be reasonably cured

within thirty (30) business days from receipt of the notice, but (1) Purdue has
begun to take corrective action to cure the alleged breach; (2) Purdue is pursuing
such corrective action with reasonable and due diligence; and (3) Purdue has
provided the Attorney General with a detailed and reasonable time table for
curing thealleged breach.
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4 1.

Nothing herein shall prevent the Attorney General from agreeing in

writing to provide Purdue with additional time beyond the thirty (30) business-day period
to respond to the notice.
42.

Nothing herein shall be construed to exonerate any failure to comply with

any provision of this Judgment after the date of entry or to compromise the authority of
the Signatory Attorney General to initiate a proceeding for failure to comply. Further,
nothing in this subsection shall be construed to limit the authority of the Signatory
' Attorney General to protect the interests of the State,
43.

The Signatory Attorney General represents that he or she will seek

enforcement of the provisions of this Judgment with due regard for fairness and, in so
doing, shall take into account efforts that Purdue has taken to cure any claimed violation
of this Judgment,
44.

Upon giving Purdue thirty (30) business days to respond to the notification

described in Paragraph 39 above, the Attorney General shall be permitted to request and
Purdue shall produce relevant, non-privileged, non-work-product records and documents
in the possession, custody or control of Purdue that relate to Purdue's compliance with
each provision of this Judgment as to which legally sufficient cause has been shown.
IX.
45.

MODIFICATION OF CERTAIN OPERATIONAL PROVISIONS
Any party to this Judgment may petition the Court for modification on

thirty (30) days’ notice to all other parties to this Judgment. Purdue may petition for
modification if it believes that the facts and circumstances that led to the Attorney
General’s action against Purdue have changed in any material respect. The parties by
stipulation may agree to a modification o f this Judgment, which agreement shall be
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presented to this Court for consideration; provided that the parties may jointly agree to a
modification only by a written instrument signed by or on behalf o f both Purdue and the
Attorney General. If Purdue wishes to seek a stipulation for a modification from the
State, it shall send a written request for agreement to such modification to the Attorney
General at least 30 days prior to filing a motion with the Court for such modification.
Within 30 days of receipt from Purdue of a written request for agreement to modify, the
Attorney General shall notify Purdue in writing if the Attorney General agrees to the
requested modification. The Attorney General shall not unreasonably withhold his/her
consent to the modification.
X.
46,

PENALTIES FOR FAILURE TO COMPLY

The State may assert any claim that Purdue has violated this Judgment in a

separate civil action to enforce this Judgment, or to seek any other relief afforded by law.
In any such action or proceeding, relevant evidence of conduct that occurred before the
Effective Date shall be admissible on any material issue, including alleged willfulness,
intent, knowledge, or breach, to the extent permitted by law. By this Paragraph, Purdue
does not waive any evidentiary objection or any other objection it may have as permitted
by law to the admissibility o f any such evidence.
XL
47.

COMPLIANCE WITH ALL LAWS

Except as expressly provided in this Judgment, nothing in this Judgment

shall be construed as;
(a)

relieving Purdue of its obligation to comply with all state laws, regulations

or rules, or granting permission to engage in any acts or practices prohibited by such law,
regulation or rule; or
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(b)

limiting or expanding in any way any right the State may otherwise have

to obtain information, documents or testimony from Purdue pursuant to any state law,
regulation or rule, or any right Purdue may otherwise have to oppose any subpoena, civil
investigative demand, motion, or other procedure issued, served, filed, or otherwise
employed by the State pursuant to any such state law, regulation, or rule.
XII.
48.

NOTICES

Any notices required to be sent to the State or to Purdue by this Judgment

shall be sent by overnight United States mail. The documents shall be sent to the
following addresses:
For the State:
Christina M. Moylan, Assistant Attorney General
Office of the Maine Attorney General
111 Sewall Street
6 State House Station
Augusta, Maine 04333-0006
For Purdue:
Vice President, Associate General Counsel
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431
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FO R PU R D U E

Robin E. Abrams
Vice President, Associate General Counsel
Purdue Pharma L.P.
The Purdue Frederick Company
Purdue Pharma Inc.
Tel: 203-588-8477

2020 K Street, N.W.
Washington, D.C. 20006-1806
Tel: 202-373-6218
Fax: 202-373-6001
M E Bar No. 002504
Date:

/ V y

DCDOCS/681481.1

L7 2 m i

(

FO R THE STATE

ATTORNEY GENERAL G. STEVEN ROWE

By:

Date:

— -______
Christina M. Moylan, A ssistantA ttom ey General
Office o f the M aine Attorney General
111 Sewall Street
6 State House Station
Augusta, M aine 04333-0006

Cl . ^ - 0 6~?
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STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO.

STATE OF MAINE,
Plaintiff,
v.
PURDUE PHARMA L.P.,
PURDUE PHARMA INC.; and
THE PURDUE FREDERICK COMPANY, INC.
(dba THE PURDUE FREDERICK COMPANY)
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

)
)
)
)
)
)

COMPLAINT

)
)
)
)
)
)
)
)
)

Defendants

1.

This civil action is brought by the State of Maine, through Attorney General G.

Steven Rowe, pursuant to the Maine Unfair Trade Practices Act arising out o f the Defendants’ unfair
and deceptive marketing o f the opioid painkiller OxyContin. Although OxyContin is a Schedule II
narcotic with an abuse profile and addictive qualities similar to morphine, Purdue aggressively
promoted OxyContin to doctors, nurses and consumers as a first-choice analgesic for treatment o f a
wide variety o f pain symptoms. While it expanded the market for OxyContin, Purdue avoided and
minimized the known risks o f OxyContin abuse, addiction and diversion.

Purdue failed to

adequately wain doctors or consumers o f OxyContin’s significant risks and failed to take reasonable
steps to guard against OxyContin abuse and diversion, instead striving to “educate” doctors and
consumers that concerns over abuse, addiction and diversion o f OxyContin were misplaced.
Purdue’s aggressive promotion o f OxyContin led to a dramatic increase in OxyContin prescriptions,

which in turn furthered an increase in OxyContin abuse and diversion from legitimate users to illicit
use o f OxyContin.

THE PARTIES
2.

The plaintiff, State o f Maine, is represented by the Attorney General who brings this

action in the public interest pursuant to 5 M.R.S.A. § 209.
3.

Defendant Purdue Pharma L.P. is a Delaware limited partnership with its principal

place o f business at One Stamford Forum, Stamford, Connecticut. At all times relevant to this
Complaint, Purdue Pharma L.P. has been in the business o f designing, testing, manufacturing,
labeling, advertising, promoting, marketing, selling, and/or distributing OxyContin throughout the
United States, including the State o f Maine.
4.

Defendant Purdue Pharma Inc. is a New York corporation with its principal place o f

business at One Stamford Forum, Stamford, Connecticut. A t all times relevant to this Complaint,
Purdue Pharma Inc. has been in the business o f designing, testing, manufacturing, labeling,
advertising, promoting, marketing, selling, and/or distributing OxyContin throughout United States,
including the State o f Maine. Purdue Pharma Inc. is the general partner o f Purdue Pharma L.P., and
at all relevant times has supervised and managed the operations and affairs o f its subsidiary and
affiliate, Purdue Pharma, L.P.
5.

Defendant The Purdue Frederick Company Inc. (d/b/a/ The Purdue Frederick

Company) is a New York corporation with its principal place o f business at One Stamford Forum,
Stamford, Connecticut. At all times relevant to this Complaint, The Purdue Frederick Company,
Inc. has been in the business of designing, testing, manufacturing, labeling, advertising, promoting,
marketing, selling, and/or distributing OxyContin throughout United States, including the State of

Maine.

6.

Because the marketing conduct alleged in this Complaint concerns all defendants, in

this complaint all defendants are collectively referred to as “Purdue.”
JURISDICTION AND VENUE
7.

This court has jurisdiction over the subject matter and defendants o f this action

pursuant to 5 M.R.S.A. § 209.
8.

In accordance with 5 M.R.S.A. § 209, venue is proper in this Court,

9.

The Maine Unfair Trade Practices Act, 5M.R.S.A. § 205-A el seq., makes unlawful

unfair or deceptive acts or practices in the conduct o f any trade or commerce, and authorizes the
Attorney General to bring enforcement actions to obtain permanent injunctive relief and recover
restitution and civil penalties up to $10,000 for each intentional violation. 5 M.R.S.A. § 207,209.
Ta c t s
P u rd u e M anufactures and Sells OxyContin, a Schedule I I N arcotic Opioid
Designed to T re a t Serious, Long-Term P ain
10.

OxyContin is an opioid analgesic -- a narcotic substance that relieves a person’s

pain without causing the loss o f consciousness. OxyContin is a controlled-release form of
oxycodone hydrochloride. Oxycodone is a very powerful pain reliever similar to morphine, and
is the active ingredient in OxyContin as well as oxycodone-combination drugs such as Percocet,
Percodan and Tylox.
11.

Purdue developed and manufactures OxyContin. OxyContin’s controlled release

o f oxycodone purports to facilitate 12-hour dosing for OxyContin, which distinguished it from
other oxycodone tablets typically administered in 4 to 6 hour doses. Due in part to its controiled3

release feature, OxyContin contains more oxycodone than other oxycodone drugs.
12.

OxyContin is a Schedule II narcotic, which means its manufacture and

distribution is subject to the Drug Enforcement Agency’s (“DEA”) regulation and control,
Classification o f OxyContin as a Schedule II controlled substance means that the DEA has
determined that OxyContin: i) has a high potential for abuse, ii) has been accepted for medical
use in the United States subject to severe restrictions, and iii) abuse may lead to severe
psychological or physical dependence.
13.

As reflected by the DEA’s oversight, OxyContin has an abuse profile, and

addictive qualities, similar to morphine. Among other things, this means that: first, OxyContin
users experience euphoria, making the drag prone to abuse (i.e., non-medical use); second,
OxyContin causes physical dependence in a short time, meaning that a user will experience
withdrawal symptoms upon terminating use; and third, tolerance is common, meaning that, over
time, dosage often must increase in order to provide the same level o f pain relief.
14.

In sum, opioids like OxyContin cause physical dependence and are prone to abuse

and addiction. As a result, doctors have traditionally, and correctly, exercised caution in
prescribing opioids, weighing their analgesic effect against the risks o f dependence, addiction,
abuse, and diversion from legitimate patients to illicit, non-medical use,
15.

Although OxyContin posed the same risks as MS Contin and other opioids,

Purdue, as part o f its marketing strategy, sought to position OxyContin differently from other
opioids by avoiding or minimizing the drug’s known risks.
16.

In December 1995, the FDA approved the use o f OxyContin for the following

“indications,” that is, the circumstances for which the FDA has determined that a drug is safe and
4

effective;
Indications: “OxyContin Tablets are a controlled-release oral formulation o f
oxycodone hydrochloride indicated for the management o f moderate-to-severe
pain where use of an opioid analgesic is appropriate for more than a few days.”
17.

In 2001, the FDA changed the OxyContin indications. OxyContin is now

indicated for the “management o f moderate-to-severe pain when a continuous around-the-clock

analgesic is neededfor an extended period o f lime."
18.

Since 1995, the FDA also has restricted the appropriate marketing and use of

OxyContin as reflected in the OxyContin label. Among other things, the FDA has determined
that OxyContin, because it has not been shown to be safe and effective for these uses, should not
be promoted:
•

for use as a prn analgesic. “Prn” means as needed, or as required.

•

for use as a preemptive analgesia (pre-operative), that is, not to be administered in
advance o f an operation for expected pain.

•

for post-operative pain h i patients not already on OxyContin.

•

for post-operative pain unless the pain is moderate-to-severe and expected to
persist for extended period.

•

where contraindicated for patients with significant respiratory depression, acute or
severe bronchial asthma or hypercarbia, or with paralytic ileus.
P u rd u e Prom oted O xyContin through a
M ultifaceted M ark etin g Cam paign

19.

Purdue has marketed OxyContin to doctors, dentists, nurses, other healthcare

professionals, and patients. Purdue’s goals have been to increase the number o f doctors
prescribing OxyContin, increase the number o f patients taking OxyContin, and increase the
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OxyContin dosages prescribed by doctors, all in order to increase OxyContin sales and generate
profits for Purdue.
20.

Purdue has, at various times:

a)

employed hundreds o f sales representatives paid to visit with doctors, nurses,
pharmacists and other health care professionals to expand the prescription writing
base and increase prescription writing for OxyContin;

b)

prepared and distributed sales aids, visuals, hand outs, and “leave behind”
promotional items to be used by sales representatives and distributed to healthcare
professionals;

c)

conducted seminars, trainings and purported educational programs for health care
professionals to promote treatment o f pain via increased opioid usage, specifically
OxyContin;

d)

placed OxyContin advertisements in medical journals and other publications
directed at healthcare professionals;

e)

maintained websites directed at patients, patient families, and healthcare
professionals promoting pain treatment, specifically via prescribing OxyContin or
other opioids;

21.

Purdue’s sales efforts are directed to: i) get doctors to prescribe and nurses to

recommend OxyContin, ii) ensure that hospitals and managed care organizations place
OxyContin on their drug formularies and treat it favorably vis-a-vis other painkillers, iii)
encourage pharmacies to stock OxyContin, in all prescription strengths, and iv) encourage
hospitals and long term care facilities to purchase and use OxyContin for their patients.
22.

The bulk o f sales representatives’ efforts focus on visiting doctors, nurses and

other medical staff, Purdue provides its sales representatives with precise information on
doctors’ prescribing histories for OxyContin and other opioid painkillers. Armed with this
information, Purdue and its sales representatives identify “core” physicians and “A -l” sales
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targets, who are deemed to be actual or potential high-volume prescribes of OxyContin.
23.

Purdue sales representatives visited these doctors and their staffs to encourage use

o f OxyContin. I f a doctor prescribed opioids other than OxyContin, Purdue sales reps
encouraged them to switch to OxyContin. If a doctor already prescribed OxyContin, Purdue
sales representatives encouraged OxyContin for more patients, for broader uses, and in increased
dosages or strengths.
24.

Purdue linked sales representatives’ compensation directly to increased

OxyContin prescribing by those doctors and institutions in die representatives’ territory, as
discussed further below.
25.

Purdue designed its seminars, trainings and “educational” programs for doctors,

pharmacists and nurses to serve the same goals as Purdue’s office sales visits: promote
OxyContin as the opioid o f choice, get healthcare professionals “comfortable” with prescribing
high strength narcotic opioids, and ultimately increase OxyContin prescriptions.
26.

Regardless o f the promotion medium, Purdue and its sales representatives echoed

several simple OxyContin sales messages, consistently reflected in Purdue’s advertisements,
marketing plans and instructions to sales representatives. With respect to encouraging doctors to
prescribe OxyContin, Purdue sought to:
•

“enhance the acceptance o f opioids for non-cancer pain,” and, with respect to
OxyContin, avoid any stigma attached to use of opiates;

•

expand OxyContin tablets use in non-malignant pain market by positioning it as
“tlie one to start with and the one to stay with;”

•

establish OxyContin as the first-line choice at Step 2 o f the WHO pain ladder
(mild to moderate pain);
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•

increase the use o f OxyContin tablets for a wide variety o f conditions, and for
acute and sub-acute pain (e.g., “post-op pain, trauma, fractures”); and

•

encourage assessment o f pain by physicians and communication o f pain by
patients, and attach an emotional aspect to non-cancer pain so physicians treat it
more aggressively.

27.

W ith respect to the characteristics o f OxyContin itself, Purdue’s marketing

emphasized:

28.

•

that OxyContin is strong (“It Works”);

•

the duration o f pain control -- that unlike other oxycodone medication, OxyContin
need only be taken every 12 hours;

•

the convenience o f 12 horn- dosing as compared to 4 or 6 hour analgesics (print
ads showing six dosage cups vs. two and stating “the hard way vs. the easy way”);

•

that OxyContin acts quickly —that the onset of analgesia is within one hour in
m ost patients; and

•

that OxyContin was “appropriate for a wide range o f patients, ”
Purdue promoted OxyContin to a wide variety o f doctors, without regard for their

training or experience prescribing opioids, encouraging OxyContin for an ever-increasing list o f
conditions, and patient types. While expanding the market in this way, Purdue failed to
adequately account for known health and safety risks o f OxyContin, especially the risks o f
OxyContin abuse, dependence, addiction and diversion.

P u rd u e 's M arketing Strategy was to Steadily E xpand OxyContin Usage
from C ancer P ain T reatm en t to a W ide A rray of Ailments
29.

A t the outset of the OxyContin launch, Purdue briefly marketed OxyContin
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principally for treatment of chronic pain in cancer patients. That quickly changed. Beginning in
1996, Purdue consistently expanded: a) the types o f doctors and healthcare professionals to
whom it promotes OxyContin; b) the classes o f patients for whom it encourages OxyContin to be
prescribed; and c) the array o f diseases and types o f pain for which it promotes OxyContin use.
30.

One step in Purdue’s plan to expand OxyContin use to all sorts o f pain was its

decision to focus its sales efforts on primary care physicians (“PCPs”).
31.

Purdue targeted PCPs as a fruitful avenue to increased OxyContin sales. Sales

representatives visited thousands o f primary care physicians and sought to convince them that
OxyContin was an appropriate first-line painkiller for a wide variety of ailments. More than half
o f doctor visits by Purdue sales reps were to PCPs. The aggressive marketing to PCPs paid off:
Since 2002, PCPs have accounted for nearly half o f all OxyContin prescriptions.
32.

Purdue’s promotional efforts also targeted additional types o f physicians,

eventually including surgeons, gerontologists, rheumatologists, orthopedics, arthritis specialists,
obstetricians and gynecologists, emergency medicine physicians, and dentists. Purdue failed to
take meaningful steps to educate these doctors on the risks o f opioid use, abuse, addiction and
diversion. Instead, Purdue repeated its simple sales messages: pain is undertreated, OxyContin
provides easy dosing and prompt relief, and is the “one to start with and to stay with.”
33.

Purdue consistently expanded the pain ailments for which it aggressively

promoted OxyContin, without a concomitant focus on limiting OxyContin to serious and
prolonged pain.
34.

As Purdue’s promotional activities expanded the proposed uses for OxyContin -

to include many diseases and many types of pain - Purdue’s marketing strategy minimized
9

OxyContin’s risks. Instead o f recommending caution in the use o f a Schedule II narcotic with an
abuse profile similar to morphine, Purdue in essence pitched OxyContin as simply a powerful
pain reliever —for many types o f pain and for many types sorts o f patients - with few
precautions to guard against its capacity for abuse, dependence, addiction and diversion.
35.

Purdue also failed to closely follow appropriate step therapy and instead promoted

OxyContin as the first-line pain reliever that could be used to treat all levels of pain - “the one to
start with and stay with” and “the easy way.”
36.

Purdue’s sales strategy to expand OxyContin’s prescriber base and patient

population was successful. Within years o f its launch and through the present, OxyContin was
and is prescribed by a wide range o f doctors for a wide range o f pain ailments.

While Expanding the Prescriber Base and Usage of OxyContin,
Purdue Failed to Adequately Focus on OxyContin’s Health and Safety Risks,
Especially the Risks Relnted to Abuse and Diversion
37.

From its product launch, Purdue knew that OxyContin was prone to abuse,

dependence, addiction and diversion. But the linchpin o f Purdue’s marketing strategy was to
distinguish OxyContin from other opioids and their well known risk o f abuse, and to avoid the
stigma attached to these other opioids, particularly morphine. Purdue’s sales strategy focused on
getting doctors “comfortable” with prescribing OxyContin, even though prescribing opioids
warrants that doctors exercise caution, and OxyContin did not warrant different treatment.
38.

In 2001, amidst significant media coverage o f widespread OxyContin abuse,

diversion and addiction, the FDA required Purdue to significantly alter its label to provide a socalled “black box” warning, including the following:
Warning: OxyContin is an opioid agonist and a Schedule II controlled
10

substance with an abuse liability similar to morphine.
OxyContin Tablets are to be swallowed whole, and are not to be broken,
chewed or crushed. Taking broken, chewed or crushed OxyContin Tablets leads
to rapid release and absorption o f a potentially fatal dose o f oxycodone.
39.

Even after the FDA required Purdue to bolster its OxyContin warning, Purdue

continued to minimize the risks o f abuse, addiction and diversion in its marketing. Instead,
Purdue repeated its message that pain is undertreated, that patients deserve opioid treatment, and
that OxyContin is the answer. Any meaningful message on the risks o f abuse, addiction and
diversion would have undermined Pui-due’s sales objectives, and Purdue avoided it.
40.

Purdue sought to portray “addiction” to opioids as exceedingly rare. By way o f

example, Purdue’s videotape “From One Patient to Another,” advised patients that “Less than
1% of patients taking opioids actually become addicted,” A Purdue pamphlet entitled
“Counseling Your Patients and Families Regarding the Use o f Opioids,” stated: “Many patients - and family members - will be surprised to discover that fewer than \% o f opioid-using patients
become addicted.” Purdue’s focus on "addiction,” narrowly defined, to the exclusion o f broader
concepts o f psychological dependence, physical dependence, tolerance and abuse, made its
representations misleading.
41.

I f doctors expressed concern over using OxyContin due to its capacity for abuse,

dependence or addiction, Purdue trained its sales representatives to avoid and minimize those
concerns.
42.

Although Purdue, in response to public scrutiny o f widespread OxyContin abuse,

has claimed to implement programs designed to guard against diversion and abuse, it has
11

continued to try to convince doctors that their concerns of addiction, dependence and abuse are
misplaced.
P urdue Employed a Sales A p p ro ach and Incentive System th a t Exacerbnfcd, R ath er T han
G uarded Against, th e R isk of OxyContiu Abuse, Addiction and Diversion
43.

Purdue sales representatives were compensated in large measure for increasing die

volume o f OxyContin prescribed and sold. Purdue’s sales goals were plain: to increase the
number o f doctors prescribing OxyContin, to increase the number o f prescriptions written by
each, and to increase dosages o f OxyContin. Purdue’s sales approach and incentive system failed
to adequately balance Purdue’s desire for increased OxyContin sales with safeguards against
OxyContin abuse, addiction and diversion.
44.

Both through its compensation structure and through its sales managers, Purdue

cultivated a high pressure environment for its sales representatives. This pressure to increase
sales was not properly balanced against public safety and failed to account for the known risks o f
OxyContin.
45.

Purdue also instructed its sales representatives to focus their sales efforts on those

doctors who already prescribed the greatest amount o f OxyContin, urging them to write more
prescriptions for more patients. Using detailed prescribing data on doctors, Purdue sales
representatives strove to increase “new starts” and increase prescription volume by these key
prescribes.
46.

These aspects o f Purdue’s sales and incentive system all served to promote, not

guard against, OxyContin abuse, diversion and addiction.
47.

Purdue also failed to use its detailed prescribing information on doctors to guard
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against OxyContin abusé and diversion. Purdue, since OxyContin’s launch, purchased detailed
prescribing data from IMS Health (“IMS data”), showing the prescribing history and patterns o f
doctors, including the number o f OxyContin prescriptions written, the dosages, as well as the
same prescribing information with respect to competing opioids and other drugs. Purdue
provides each sales representative this prescribing information for target doctors in then territory.
48.

Purdue could have used the prescribing data to readily identify potential sources

o f abuse and diversion, such as “pill mills” that divert OxyContin to the illicit street market.
Purdue then could have employed meaningful internal measures to guard against abuse and
diversion risks. For instance, Purdue could have visited those doctors to review pain
documentation practices or otherwise protect against potential abuse or diversion. Or, the
company could have shared with law enforcement those prescribing patterns that evidenced a
risk o f abuse or diversion. For years, Pur-due did not take those steps.
49.

Purdue, notwithstanding its marketing claims focused on fighting abuse and

diversion, declined to use the IMS prescribing data to protect against abuse and diversion risks.
Purdue sales representatives instead targeted the highest prescribers and encouraged them to
prescribe more OxyContin, in larger doses, to more patients. Purdue’s marketing practices thus
exacerbated the abuse and diversion risks,
50.

Purdue’s OxyContin marketing resulted in dramatic increases in OxyContin

prescriptions.
.

51.

On or about October 12,2004, Purdue entered into a tolling agreement with the

State o f Maine with respect to the State o f Maine’s claims against Purdue, tolling the application
o f the statute o f limitations from May 12,2004 through the filing o f this Complaint.
13

CAUSES OF ACTION

Count One
(Unfair or Deceptive Acts or Practices in violation o f the Maine Unfair Trade Practices Act)
52.

The State o f Maine incorporates by reference the allegations o f paragraphs 1 through

51 o f the Complaint.
53.

Purdue engaged in unfair or deceptive acts or practices in its marketing, promotion

and sale o f OxyContin, including without limitation:
a)

aggressively marketing OxyContin to a broad variety o f doctors and patients, for an
ever expanding array o f ailments, sometimes contrary to its label and indications,
while failing to adequately disclose and reasonably warn o f and guard against the
health and safety risks associated with OxyContin, including the risks associated with
misuse, abuse, dependence, addiction and diversion;

b)

avoiding or minimizing the known risks o f OxyContin, including the risks of abuse,
dependence, addiction and diversion; and

c)

employing a sales and incentive program that failed to reasonably guard against
OxyContin abuse and diversion.

54.

Purdue knew or should have known that its conduct was unfair or deceptive in

violation o f the Maine Unfair Trade Practices Act.
RELIEF REQUESTED
WHEREFORE, the Plaintiff requests that this court:
1.

Enter j udgment in favor o f the Plaintiff and against the defendants under the Maine

Unfair Trade Practices Act, and permanently enjoin Purdue from engaging in unfair or deceptive acts
and practices in the marketing and promotion o f OxyContin.
2.

Order the defendants to pay civil penalties for each intentional violation o f the Maine

Unfair Trade Practices Act;
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3.

Order defendants to pay the costs o f investigation and litigation, including attorneys5

fees, pursuant to 5 M.R.S.A. § 209; and
4.

Grant such other and further relief as the Court deems equitable and proper.

Dated at Augusta, Maine this 8th day o f May, 2007.

Respectfully submitted,
PLAINTIFF STATE OF MAINE
G. STEVEN ROWE
ATTORNEY GENERAL
BY:
Christina M. Moylan
Assistant Attorney General
Department o f Attorney General
6 State House Station
Augusta, Maine 04333-0006
Maine Bar No, 7095
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO.

STATE OF MAINE
KENNEBEC, SS.

)
STATE OF MAINE,

)

)
Plaintiff,

)

)
v.

) COMPLAINT

)
PURDUE PHARMA L.P.,
)
PURDUE PHARMA INC.; and
)
THE PURDUE FREDERICK COMPANY, INC. )
(dba THE PURDUE FREDERICK COMPANY) . )
One Stamford Forum
)
201 Tresser Boulevard
)
Stamford, CT 06901-3431
)

)
Defendants

1.

)

This civil action is brought by the State o f Maine, through Attorney General G.

Steven Rowe, pursuant to the Maine Unfair Trade Practices Act arising out o f the Defendants’ unfair
and deceptive marketing o f the opioid painkiller OxyContin. Although OxyContin is a Schedule II
narcotic with an abuse profile and addictive qualities similar to morphine, Purdue aggressively
promoted OxyContin to doctors, nurses and consumers as a first-choice analgesic for treatment o f a
wide variety of pain symptoms. While it expanded the market for OxyContin, Purdue avoided and
minimized the known risks o f OxyContin abuse, addiction and diversion.

Purdue failed to

adequately warn doctors or consumers o f OxyContin’s significant risks and failed to take reasonable
steps to guard against OxyContin abuse and diversion, instead striving to “educate” doctors and
consumers that concerns over abuse, addiction and diversion o f OxyContin were misplaced.
Purdue’s aggressive promotion o f OxyContin led to a dramatic increase in OxyContin prescriptions,

which in turn furthered an increase in OxyContin abuse and diversion from legitimate users to illicit
use o f OxyContin.

THE PARTIES
2.

The plaintiff, State o f Maine, is represented by the Attorney General who brings this

action in the public interest pursuant to 5 M .R.SA. § 209.
3.

Defendant Purdue Pharma L.P. is a Delaware limited partnership with its principal

place o f business at One Stamford Forum, Stamford, Connecticut. At all times relevant to this
Complaint, Purdue Pharma L.P. has been in the business o f designing, testing, manufacturing,
labeling, advertising, promoting, marketing, selling, and/or distributing OxyContin throughout the
United States, including the State o f Maine.
4.

Defendant Purdue Pharma Inc, is a New York corporation with its principal place o f

business at One Stamford Forum, Stamford, Connecticut. A t all times relevant to this Complaint,
Purdue Phanna Inc. has been in the business o f designing, testing, manufacturing, labeling,
advertising, promoting, marketing, selling, and/or distributing OxyContin throughout United States,
including the State o f Maine. Purdue Pharma Inc. is the general partner o f Purdue Pharma L.P., and
at all relevant times has supervised and managed die operations and affairs o f its subsidiary and
affiliate, Purdue Pharma, L.P.
5.

Defendant The Purdue Frederick Company Inc. (d/b/a/ The Purdue Frederick

Company) is a New York corporation with its principal place o f business at One Stamford Forum,
Stamford, Connecticut. At all times relevant to this Complaint, The Purdue Frederick Company,
Inc. has been in the business-of designing, testing, manufacturing, labeling, advertising, promoting,
marketing, selling, and/or distributing OxyContin throughout United States, including the State of

Maine.

6.

Because the marketing conduct alleged in this Complaint concerns all defendants, in

this complaint all defendants are collectively referred to as “Purdue.”
JURISDICTION AND VENUE
7.

This court has jurisdiction over the subject matter and defendants o f this action

pursuant to 5 M.R.S.A. § 209.
8.
9.

' In accordance with 5 M.R.S.A. § 209, venue is proper in this Court.
The Maine Unfair Trade Practices Act, 5 M.R.S.A. § 205-A ef seq., makes unlawful

unfair or deceptive acts or practices in the conduct o f any trade or commerce, and authorizes the
Attorney General to bring enforcement actions to obtain permanent injunctive relief and recover
restitution and civil penalties up to $10,000 for each intentional violation. 5 M.R.S.A. § 207,209.
Pa c t s

Purdue Manufactures and Sells OxyContin, a Schedule II Narcotic Opioid
Designed to Treat Serious, Long-Term Pain
10.

OxyContin is an opioid analgesic —a narcotic substance that relieves a person’s

pain without causing the loss o f consciousness. OxyContin is a controlied-release form of
oxycodone hydrochloride. Oxycodone is a very powerful pain reliever similar to morphine, and
is the active ingredient in OxyContin as well as oxycodone-combination drugs such as Percocet,
Percodan and Tylox.
11.

Purdue developed and manufactures OxyContin. OxyContin’s controlled release

o f oxycodone purports to facilitate 12-hour dosing for OxyContin, which distinguished it from
other oxycodone tablets typically administered in 4 to 6 hour doses. Due in part to its controlled3

release feature, OxyContin contains more oxycodone than other oxycodone drugs.
12.

OxyContin is a Schedule II narcotic, which means its manufacture and

distribution is subject to the D rug Enforcement Agency’s (“DEA”) regulation and control.
Classification o f OxyContin as a Schedule II controlled substance means that the DEA has
determined that OxyContin: i) has a high potential for abuse, ii) has been accepted for medical
use in the United States subject to severe restrictions, and iii) abuse may lead to severe
psychological or physical dependence.
13.

As reflected by the DEA’s oversight, OxyContin has an abuse profile, and

addictive qualities, similar to morphine. Among other tilings, this means that: first, OxyContin
users experience euphoria, making the drug prone to abuse (i.e., non-medical use); second,
OxyContin causes physical dependence in a short time, meaning that a user will experience
withdrawal symptoms upon terminating use; and third, tolerance is common, meaning that, over
time, dosage often must increase in order to provide the same level o f pain relief.
14.

In sum, opioids like OxyContin cause physical dependence and are prone to abuse

and addiction. As a result, doctors have traditionally, and correctly, exercised caution in
prescribing opioids, weighing their analgesic effect against the risks o f dependence, addiction,
abuse, and diversion from legitimate patients to illicit, non-medical use.
15.

Although OxyContin posed the same risks as MS Contin and other opioids,

Purdue, as part o f its marketing strategy, sought to position OxyContin differently from other
opioids by avoiding or minimizing the drug’s known risks.
16.

In December 1995, the FDA approved the use o f OxyContin for the following

“indications,” that is, the circumstances for which the FDA has determined that a drug is safe and
4

effective:
Indications: “OxyContin Tablets are a controlled-release oral formulation o f
oxycodone hydrochloride indicated for the management o f moderate-to-severe
pain where use o f ail opioid analgesic is appropriate for more than a few days,”
17.

In 2001, the FDA changed the OxyContin indications. OxyContin is now

indicated for the “management o f moderate-to-severe pain when a continuous around-the-clock

analgesic is neededfor an extended period o f time. ”
18.

Since 1995, the FDA also has restricted the appropriate marketing and use o f

OxyContin as reflected in the OxyContin label. Among other things, the FDA has determined
that OxyContin, because it has not been shown to be safe and effective for these uses, should not
be promoted:
•

for use as a prn analgesic, “Prn” means as needed, or as required.

•

for use as a preemptive analgesia (pre-operative), that is, not to be administered in
advance o f an operation for expected pain.

•

for post-operative pain hi patients not already on OxyContin.

•

for post-operative pain unless the pain is moderate-to-severe and expected to
persist for extended period.

•

where contraindicated for patients with significant respiratory depression, acute or
severe bronchial asthma or hypercarbia, or with paralytic ileus.

Purdue Promoted OxyContin through a
Multifaceted Marketing Campaign
19.

Purdue has marketed OxyContin to doctors, dentists, nurses, other healthcare

professionals, and patients. Purdue’s goals have been to increase the number o f doctors
prescribing OxyContin, increase the number o f patients taking OxyContin, and increase the
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OxyContin dosages prescribed by doctors, all in order to increase OxyContin sales and generate
profits for Purdue.
20.

Purdue has, at various times:

a)

employed hundreds o f sales representatives paid to visit with doctors, nurses,
pharmacists and other health care professionals to expand the prescription writing
base and increase prescription writing for OxyContin;

b)

prepared and distributed sales aids, visuals, hand outs, and “leave behind”
promotional items to be used by sales representatives and distributed to healthcare
professionals;

c)

conducted seminars, trainings and purported educational programs for health care
professionals to promote treatment o f pain via increased opioid usage, specifically
OxyContin;

d)

placed OxyContin advertisements in medical journals and other publications
directed at healthcare professionals;

e)

maintained websites directed at patients, patient families, and healthcare
professionals promoting pain treatment, specifically via prescribing OxyContin or
other opioids;

21.

Purdue’s sales efforts are directed to: i) get doctors to prescribe and muses to

.

recommend OxyContin, ii) ensure that hospitals and managed care organizations place
OxyContin on their drug formularies and treat it favorably vis-a-vis other painkillers, iii)
encourage pharmacies to stock OxyContin, in all prescription strengths, and iv) encourage
hospitals and long term care facilities to purchase and use OxyContin for their patients.
22.

The bulk o f sales representatives’ efforts focus on visiting doctors, nurses and

other medical staff. Purdue provides its sales representatives with precise information on
doctors’ prescribing histories for OxyContin and other opioid painkillers. Armed with this
information, Purdue and its sales representatives identify “core” physicians and “A -l” sales

6

targets, who are deemed to be actual or potential high-volume prescribes o f OxyContin.
23.

Purdue sales representatives visited these doctors and their staffs to encourage use

o f OxyContin. I f a doctor prescribed opioids other than OxyContin, Purdue sales reps
encouraged them to switch to OxyContin. If a doctor already prescribed OxyContin, Purdue
sales representatives encouraged OxyContin for more patients, for broader uses, and in increased
dosages or strengths.
24.

Purdue linked sales representatives’ compensation directly to increased

OxyContin prescribing by those doctors and institutions in the representatives’ territory, as
discussed further below.
25.

Purdue designed its seminars, tr ainings and “educational” programs for doctors,

pharmacists and nurses to serve the same goals as Purdue’s office sales visits: promote
OxyContin as the opioid o f choice, get healthcare professionals “comfortable” with prescribing
high strength narcotic opioids, and ultimately increase OxyContin prescriptions.
26.

Regardless o f the promotion medium, Purdue and its sales representatives echoed

several simple OxyContin sales messages, consistently reflected in Purdue’s advertisements,
marketing plans and instructions to sales representatives. With respect to encouraging doctors to
prescribe OxyContin, Purdue sought to:
•

“enhance the acceptance o f opioids for non-cancer pain,” and, with respect to
OxyContin, avoid any stigma attached to use of opiates;

•

expand OxyContin tablets use in non-malignant pain market by positioning it as
"the one to start with and the one to stay with;”

•

establish OxyContin as the first-line choice at Step 2 o f the WHO pain ladder
(mild to moderate pain);
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•

increase the use o f OxyContin tablets for a wide variety o f conditions, and for
acute and sub-acute pain (e.g., “post-op pain, trauma, fractures”); and

•

encourage assessment o f pain by physicians and communication o f pain by
patients, and attach an emotional aspect to non-cancer pain so physicians treat it
m ore aggressively.

27.

W ith respect to the characteristics o f OxyContin itself, Purdue’s marketing

emphasized:

28.

•

that OxyContin is strong (“It W orks”);

•

the duration o f pain control -- that unlike other oxycodone medication, OxyContin
need only be taken every 12 horns;

•

the convenience o f 12 hour dosing as compared to 4 or 6 hour analgesics (print
ads showing six dosage cups vs. two and stating “the hard way vs. the easy way”);

•

that OxyContin acts quickly —that the onset of analgesia is within one hour in
m ost patients; and

•

that OxyContin was “appropriate for a wide range o f patients.”
Purdue promoted OxyContin to a wide variety o f doctors, without regard for their

training or experience prescribing opioids, encouraging OxyContin for an ever-increasing list o f
conditions, and patient types. While expanding the market in this way, Purdue failed to
adequately account for known health and safety risks o f OxyContin, especially the risks of
OxyContin abuse, dependence, addiction and diversion.

Purdue’s Marketing Strategy was to Steadily Expand OxyContin Usage
from Cancer Pain Treatment to a Wide Array of Ailments
29.

A t the outset o f the OxyContin launch, Purdue briefly marketed OxyContin
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principally for treatment o f chronic pain in cancer patients. That quickly changed. Beginning in
1996, Purdue consistently expanded: a) the types o f doctors and healthcare professionals to
whom it promotes OxyContin; b) the classes o f patients for whom it encourages OxyContin to be
prescribed; and c) the array o f diseases and types o f pain for which it promotes OxyContin use.
30.

One step in Purdue’s plan to expand OxyContin use to all sorts o f pain was its

decision to focus its sales efforts on primary care physicians (“PCPs”).
31.

Purdue targeted PCPs as a fruitful avenue to increased OxyContin sales. Sales

representatives visited thousands o f primary care physicians and sought to convince them that
OxyContin was an appropriate first-line painkiller for a wide variety of ailments. More than half
o f doctor visits by Purdue sales reps were to PCPs. The aggressive marketing to PCPs paid off:
Since 2002, PCPs have accoimted for nearly half o f all OxyContin prescriptions.
32.

Purdue’s promotional efforts also targeted additional types o f physicians,

eventually including surgeons, gerontologists, rheumatologists, orthopedics, arthritis specialists,
obstetricians and gynecologists, emergency medicine physicians, and dentists. Purdue failed to
take meaningful steps to educate these doctors on the risks o f opioid use, abuse, addiction and
diversion. Instead, Purdue repeated its simple sales messages: pain is undertreated, OxyContin
provides easy dosing and prompt relief, and is the “one to start with and to stay with.”
33.

Purdue consistently expanded the pain ailments for which it aggressively

promoted OxyContin, without a concomitant focus on limiting OxyContin to serious and
prolonged pain.
34.

As Purdue’s promotional activities expanded the proposed uses for OxyContin -

to include many diseases and many types of pain —Purdue’s marketing strategy minimized
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OxyContin’s risks. Instead o f recommending caution in the use o f a Schedule II narcotic with an
abuse profile similar to morphine, Pindue in essence pitched OxyContin as simply a powerful
pain reliever —for many types o f pain and for many types sorts o f patients —with few
precautions to guard against its capacity for abuse, dependence, addiction and diversion.
35.

Purdue also failed to closely follow appropriate step therapy and instead promoted

OxyContin as the first-line pain reliever that could be used to treat all levels o f pain —“the one to
start with and stay with” and “the easy way.”
36.

Purdue’s sales strategy to expand OxyContin’s prescriber base and patient

population was successful. Within years of its launch and through the present, OxyContin was
and is prescribed by a wide range o f doctors for a wide range o f pain ailments.
W hile E xpanding the Prescriber B ase and Usage of OxyContin,
P u rd u e Failed to A dequately Focus on O xyC ontin’s H ealth and Safety Risks,
Especially the Risks R elated to Abuse an d Diversion
37.

From its product launch, Purdue knew that OxyContin was prone to abuse,

dependence, addiction and diversion. But the linchpin o f Purdue’s marketing strategy was to
distinguish OxyContin from other opioids and their well known risk o f abuse, and to avoid the
stigma attached to these other opioids, particularly morphine. Purdue’s sales strategy focused on
getting doctors “comfortable” with prescribing OxyContin, even though prescribing opioids
warrants that doctors exercise caution, and OxyContin did not warrant different treatment.
38.

In 2001, amidst significant media coverage o f widespread OxyContin abuse,

diversion and addiction, the FDA required Purdue to significantly alter its label to provide a socalled “black box” warning, including the following:
Warning: OxyContin is an opioid agonist and a Schedule II controlled
10

substance with an abuse liability similar to morphine.
OxyContin Tablets are to be swallowed whole, and are not to be broken,
chewed or crushed. Taking broken, chewed or crashed OxyContin Tablets leads
to rapid release and absorption o f a potentially fatal dose o f oxycodone.
39.

Even after the FDA required Purdue to bolster its OxyContin warning, Purdue

continued to minimize the risks of abuse, addiction and diversion in its marketing. Instead,
Purdue repeated its message that pain is undertreated, that patients deserve opioid treatment, and
that OxyContin is the answer. Any meaningful message on the risks o f abuse, addiction and
diversion would have undermined Purdue’s sales objectives, and Purdue avoided it.
40.

Purdue sought to portray “addiction” to opioids as exceedingly rare. By way o f

example, Purdue’s videotape “From One Patient to Another,” advised patients that “Less than
1% o f patients taking opioids actually become addicted.” A Purdue pamphlet entitled
“Counseling Your Patients and Families Regarding the Use o f Opioids,” stated: “Many patients - and family members -- will be surprised to discover that fewer than 1% o f opioid-using patients
become addicted.” Purdue’s focus on “addiction,” narrowly defined, to the exclusion o f broader
concepts o f psychological dependence, physical dependence, tolerance and abuse, made its
representations misleading.
41.

I f doctors expressed concern over using OxyContin due to its capacity for abuse,

dependence or addiction, Purdue trained its sales representatives to avoid and minimize those
concerns.
42.

Although Purdue, in response to public scrutiny o f widespread OxyContin abuse,

has claimed to implement programs designed to guard against diversion and abuse, it has
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continued to try to convince doctors that their concerns o f addiction, dependence and abuse are
misplaced.

Purdue Employed a Sales Approach and Incentive System that Exacerbated, Rather Than
Guarded Against, the Risk of OxyContin Abuse, Addiction and Diversion
43.

Purdue sales representatives were compensated in large measure for increasing the

volume o f OxyContin prescribed and sold. Purdue’s sales goals were plain: to increase the
number o f doctors prescribing OxyContin, to increase the number o f prescriptions written by
each, and to increase dosages o f OxyContin. Purdue’s sales approach and incentive system failed
to adequately balance Purdue’s desire for increased OxyContin sales with safeguards against
OxyContin abuse, addiction and diversion.
44.

Both through its compensation structure and through its sales managers, Purdue

cultivated a high pressure environment for its sales representatives. This pressure to increase
sales was not properly balanced against public safety and failed to account for the known risks o f
OxyContin.
45.

Purdue also instructed its sales representatives to focus their sales efforts on those

doctors who already prescribed the greatest amount o f OxyContin, urging them to write more
prescriptions for more patients. Using detailed prescribing data on doctors, Purdue sales
representatives strove to increase “new starts” and increase prescription volume by these key
prescribers.
46.

These aspects o f Purdue’s sales and incentive system all served to promote, not

guard against, OxyContin abuse, diversion and addiction,
47.

Purdue also failed to use its detailed prescribing information on doctors to guard
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against OxyContin abuse and diversion. Purdue, since OxyContin’s launch, purchased detailed
prescribing data from IMS Health (“IMS data”), showing the prescribing history and patterns o f
doctors, including the number o f OxyContin prescriptions written, the dosages, as well as the
same prescribing information with respect to competing opioids and other drugs. Purdue
provides each sales representative this prescribing information for target doctors in their territory.
48.

Purdue could have used the prescribing data to readily identify potential sources

o f abuse and diversion, such as “pill mills” that divert OxyContin to the illicit street market.
Purdue then could have employed meaningful internal measures to guard against abuse and
diversion risks. For instance, Purdue could have visited those doctors to review pain
documentation practices or otherwise protect against potential abuse or diversion. Or, the
company could have shared with law enforcement those prescribing patterns that evidenced a
risk o f abuse or diversion. For years, Purdue did not take those steps.
49.

Purdue, notwithstanding its marketing claims focused on fighting abuse and

diversion, declined to use the IMS prescribing data to protect against abuse and diversion risks.
Purdue sales representatives instead targeted the highest prescribes and encouraged them to
prescribe more OxyContin, in larger doses, to more patients. Purdue’s marketing practices thus
exacerbated the abuse and diversion risks.
50.

Purdue’s OxyContin marketing resulted in dramatic increases in OxyContin

prescriptions.
51.

On or about October 12,2004, Purdue entered into a tolling agreement with the

State o f M aine with respect to the State o f Maine’s claims against Purdue, tolling the application
of the statute o f limitations from May 12,2004 through the filing o f this Complaint.
13

CAUSES OF ACTION

Count One
(Unfair or Deceptive Acts or Practices in violation o f the Maine Unfair Trade Practices Act)
52.

The State o f Maine incorporates by reference the allegations o f paragraphs 1 through

51 o f the Complaint.
53.

Purdue engaged in unfair* or deceptive acts or practices in its marketing, promotion

and sale o f OxyContin, including without limitation:
a)

aggressively marketing OxyContin to a broad variety of doctors and patients, for an
ever expanding array o f ailments, sometimes contrary to its label and indications,
while failing to adequately disclose and reasonably warn of and guar d against the
health and safety risks associated with OxyContin, including the risks associated with
misuse, abuse, dependence, addiction and diversion;

b)

avoiding or minimizing the known risks o f OxyContin, including the risks o f abuse,
dependence, addiction and diversion; and

c)

employing a sales and incentive program that failed to reasonably guard against
OxyContin abuse and diversion.

54.

Purdue knew or should have known that its conduct was unfair or deceptive in

violation o f the M aine Unfair Trade Practices Act.
RELIEF REQUESTED
WHEREFORE, the Plaintiff requests that this court:
1.

Enter j udgment in favor o f the Plaintiff and against the defendants under the Maine

Unfair Trade Practices Act, and permanently enjoin Purdue from engaging in unfair or deceptive acts
and practices in the marketing and promotion o f OxyContin,
2.

Order the defendants to pay civil penalties for each intentional violation o f the Maine

Unfair Trade Practices Act;

14

3.

Order defendants to pay the costs of investigation and litigation, including attorneys’

fees, pursuant to 5 M.R.S.A. § 209; and
4.

Grant such other and further relief as the Court deems equitable and proper.

Dated at Augusta, Maine this 8th day o f May, 2007.

Respectfully submitted,
PLAINTIFF STATE OF MAINE
G. STEVEN ROWE
ATTORNEY GENERAL
BY:

(■
Christina M. Moylan
Assistant Attorney General
Department o f Attorney General
6 State House Station
Augusta, Maine 04333-0006
Maine Bar No. 7095
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